WNK1 and acute myeloid leukemia: To further assess the therapeutic potential of WNK1 for the treatment of AML, we tested two previously described selective small-molecule WNK inhibitors: the ATP-competitive WNK inhibitor WNK463 that inhibits all four WNK kinases as well as the allosteric and specific WNK1 inhibitor Compound 1220,21.